4-Carvomenthenol (Terpinen-4-ol) is an anti-inflammatory and antimicrobial agent. 4-Carvomenthenol is a fragrance ingredient used in decorative cosmetics, fine fragrances, shampoos, toilet soaps and other toiletries as well as in non-cosmetic products such as household cleaners and detergents. Its use worldwide is in the region of 1–10 metric tonnes per annum. The maximum skin level that results from the use of 4-carvementhenol in formulae that go into fine fragrances has been reported to be 0.13%. 4-Carvomenthenol has been shown to have antiviral, antibacterial, antifungal, and insecticidal effects as well as antioxidant and anti-inflammatory activities. It is a putative anitcancer agent. 4-carvementhenol exerts its antitumor effects by triggering caspase-dependent apoptosis in human melanoma cells or by inducing necrotic cell death and cell-cycle arrest in mouse mesothelioma and melanomacell lines without affecting normal cells. Caspase-dependent mitochondrial dysfunction is the mechanism of terpinen-4-ol-induced apoptosis in nonsmall lung cancer cells. Down-regulation of Bcl-2, XIAP and survivin suggests that ter-pinen-4-ol increases the susceptibility of NSCLC cells toapoptosis induction. Notably, the ability of terpinen-4-ol to induce apoptosis in NSCLC cells is p53-dependent. It has also been shown that the growth of s.c. xenograft tumors was remarkably inhibited by intratumoral injection of terpinen-4-ol, indicating that the agent also has potential for clinical anticancer activity.

Benzyl acetate is used as a fragrance ingredient and occurs in different plants and fruits, e.g., jasmine, apple, tea, plum, wine grape. It possesses a sweet and pleasant aroma, owing to which, it finds applications in personal hygiene and health care products.

Carbon monoxide (CO) is a colorless, odorless, tasteless, and nonirritating but highly toxic gas generated by both natural and manufactured processes. CO displays many physiological roles in the neuronal, cardiovascular, and immune systems, as well as in the respiratory, reproductive, gastrointestinal, and urogenital apparatus, including anti‐apoptotic, anti‐inflammatory, anti‐oxidant, anti‐proliferative, and vasodilator effects. Although many pathologies, including cancer, hematological diseases, hypertension, heart failure, inflammation, sepsis, neurodegeneration, and sleep disorders, have been linked to abnormal endogenous CO metabolism and functions, CO displays therapeutic actions. CO has demonstrated therapeutic potential against a wide range of human diseases. However, development of CO as a therapeutic agent is severely impeded, primarily due to the lack of pharmaceutically acceptable delivery forms of CO. The therapeutic use of CO is based on (i) the induction or gene transfer of HO‐1, (ii) the inhalation of gaseous CO, and (iii) the use of CO‐releasing molecules (CO‐RMs). There is a large amount of broad preclinical evidence of the benefits of CO in large and small animal models. Importantly, CO is effective both as a prophylactic and as a therapeutic in diverse models, such as malaria, organ transplantation and pulmonary hypertension. Inhaled CO and CO-RMs are in development as therapeutics; inhaled CO is being tested in Phase II clinical trials for kidney transplantation and various CO-RMs are under preclinical evaluation. The precise molecular targets for CO remain unclear with a wide range of evidence for both haem and non-haem targets. A commonality revolves around the contributions of the mitochondria and alterations in cellular bioenergetics. Inhaled CO delivery can be accomplished with an innovative delivery device. In addition strong medicinal chemistry is driving CO-RM development with efforts towards tissue specificity and the appropriate pharmacokinetic and pharmacodynamic profiling. Inhaled CO has found wide applications in basic research in examining CO’s physiological and pathological roles, yet its application in human has many limitations, such as difficulty in precise dose control, lack of portability and inability for targeted delivery, among others. In order to mitigate these limitations, a family of transition metal based CO-releasing molecules (CO-RMs) have been elegantly devised, and have shown CO-associated biological outcomes both in vitro and in vivo. Proterris is developing an inhaled carbon monoxide (CO) therapy for the treatment of idiopathic pulmonary fibrosis (IPF), delayed graft function (DGF), acute kidney injury and renal fibrosis.

Ethylhexyl triazone is a PABA-derivative used in sunscreens to absorb UVB radiation. It is marketed as Uvinul T 150 by BASF. Ethylhexyl triazone has an absorption maximum of 314 nm. Ethylhexyl triazone is not approved as an active ingredient in the U.S., but used in rare cases to boost efficacy of some products. Ethylhexyl triazone is approved for use up to 5% in EU and Japan. It blocks UVB and extremely stable, it is the most effective UVB filter. Only small concentrations are required to achieve high SPF value, has good affinity to keratin and completely insoluble in water, making it particularly good choice for water-resistant sunscreens. Very stable in light – ability to filter UV rays remains practically unchanged even when exposed to intense radiation.

Tylvalosin (TVS) is a third-generation macrolide drug used for prophylaxis and treatment of mycoplasma. Tylvalosin, the active ingredient of Aivlosin 625 mg/g Water Soluble Granules (ECO Animal Health, UK), is a modern macrolide that has shown its effectiveness in the control of porcine proliferative enteropathy, EP and swine dysentery. Aivlosin is indicated for the control of porcine proliferative enteropathy (PPE) associated with Lawsonia intracellularis infection in groups of swine in buildings experiencing an outbreak of PPE. Tylvalosin tartrate is a macrolide antibiotic that has antibacterial activity against Gram-positive, some Gram-negative organisms and mycoplasma. It acts by inhibiting protein synthesis in the bacteria cell.